Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
Clinical Pharmacology & Therapeutics2018Vol. 105(5), pp. 1148–1155
Citations Over TimeTop 10% of 2018 papers
Hans‐Georg Eichler, Nicola Bedlington, Mathieu Boudes, Jacoline C. Bouvy, André W. Broekmans, Francesca Cerreta, Stuart Faulkner, Susan R. Forda, Angelika Joos, Yann Le Cam, Mark H. Mayer, Vinciane Pirard, Solange Corriol‐Rohou
Abstract
Medicines Adaptive Pathways to Patients (MAPPs) seeks to foster access to novel beneficial treatments for the right patient groups at the earliest appropriate time in the product life-span, in a sustainable fashion. We summarize the MAPPs engagement process and critical questions to be asked at each milestone of the product life-span. These considerations are of relevance for regulatory and access pathways that strive to address the "evidence vs. access" conundrum.
Related Papers
- → <p>Identification of gender differences in ultrasound milestone assessments during emergency medicine residency training: a pilot study</p>(2019)4 cited
- → A New Milestone from Cibyra(2023)1 cited
- Ability of toddlers to recognise TV images. Clinical utility of this milestone is not established.(2000)
- → SCHEDULE PLANNING AND MANAGEMENT WITH MILESTONE IN REPETITIVE CONSTRUCTION WORK(1997)2 cited
- → IEEE milestone for Germany: the EMC society is "instrumental" in making it happen!(2016)